How has been the historical performance of Glaxosmi. Pharma?

Answer:The historical performance of Glaxosmi. Pharma shows a positive trend in net sales and profitability over the past few years, culminating in the fiscal year ending March 2025.

Breakdown:
Glaxosmi. Pharma's net sales have steadily increased from 3,128.12 Cr in March 2019 to 3,749.21 Cr in March 2025, reflecting a consistent growth trajectory. The total operating income followed a similar pattern, rising from 3,128.12 Cr in March 2019 to 3,749.21 Cr in March 2025. The company's operating profit (PBDIT) also saw significant improvement, increasing from 703.11 Cr in March 2019 to 1,323.29 Cr in March 2025, with an operating profit margin that improved from 19.21% to 31.4% over the same period. Profit before tax rose from 682.66 Cr in March 2019 to 1,259.88 Cr in March 2025, while profit after tax increased from 445.39 Cr to 927.58 Cr. The earnings per share (EPS) demonstrated a remarkable rise from 26.29 in March 2019 to 54.75 in March 2025. Furthermore, the net cash inflow improved significantly, reaching 474.00 Cr in March 2025, compared to a net outflow of 251.00 Cr in March 2023, indicating a strong cash position with closing cash and cash equivalents of 538.00 Cr in March 2025. Overall, Glaxosmi. Pharma has shown robust growth in sales, profitability, and cash flow, marking a successful financial performance in recent years.